170 related articles for article (PubMed ID: 38637846)
1. Mutational landscape of inflammatory breast cancer.
Bertucci F; Lerebours F; Ceccarelli M; Guille A; Syed N; Finetti P; Adélaïde J; Van Laere S; Goncalves A; Viens P; Birnbaum D; Mamessier E; Callens C; Bedognetti D
J Transl Med; 2024 Apr; 22(1):374. PubMed ID: 38637846
[TBL] [Abstract][Full Text] [Related]
2. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
[TBL] [Abstract][Full Text] [Related]
3. Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers.
Li X; Kumar S; Harmanci A; Li S; Kitchen RR; Zhang Y; Wali VB; Reddy SM; Woodward WA; Reuben JM; Rozowsky J; Hatzis C; Ueno NT; Krishnamurthy S; Pusztai L; Gerstein M
Genome Med; 2021 Apr; 13(1):70. PubMed ID: 33902690
[TBL] [Abstract][Full Text] [Related]
4. High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes.
Bekhouche I; Finetti P; Adelaïde J; Ferrari A; Tarpin C; Charafe-Jauffret E; Charpin C; Houvenaeghel G; Jacquemier J; Bidaut G; Birnbaum D; Viens P; Chaffanet M; Bertucci F
PLoS One; 2011 Feb; 6(2):e16950. PubMed ID: 21339811
[TBL] [Abstract][Full Text] [Related]
5. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
[TBL] [Abstract][Full Text] [Related]
7. Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors.
Bertucci F; Boudin L; Finetti P; Van Berckelaer C; Van Dam P; Dirix L; Viens P; Gonçalves A; Ueno NT; Van Laere S; Birnbaum D; Mamessier E
Oncoimmunology; 2021 May; 10(1):1929724. PubMed ID: 34104544
[No Abstract] [Full Text] [Related]
8. Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype.
Funakoshi Y; Wang Y; Semba T; Masuda H; Hout D; Ueno NT; Wang X
PLoS One; 2019; 14(9):e0222336. PubMed ID: 31532791
[TBL] [Abstract][Full Text] [Related]
9. Molecular comparison of interval and screen-detected breast cancers.
Cheasley D; Li N; Rowley SM; Elder K; Mann GB; Loi S; Savas P; Goode DL; Kader T; Zethoven M; Semple T; Fox SB; Pang JM; Byrne D; Devereux L; Nickson C; Procopio P; Lee G; Hughes S; Saunders H; Fujihara KM; Kuykhoven K; Connaughton J; James PA; Gorringe KL; Campbell IG
J Pathol; 2019 Jun; 248(2):243-252. PubMed ID: 30746706
[TBL] [Abstract][Full Text] [Related]
10. Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer.
Luo R; Chong W; Wei Q; Zhang Z; Wang C; Ye Z; Abu-Khalaf MM; Silver DP; Stapp RT; Jiang W; Myers RE; Li B; Cristofanilli M; Yang H
NPJ Breast Cancer; 2021 Jun; 7(1):72. PubMed ID: 34075047
[TBL] [Abstract][Full Text] [Related]
11. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers.
Masuda H; Baggerly KA; Wang Y; Iwamoto T; Brewer T; Pusztai L; Kai K; Kogawa T; Finetti P; Birnbaum D; Dirix L; Woodward WA; Reuben JM; Krishnamurthy S; Symmans W; Van Laere SJ; Bertucci F; Hortobagyi GN; Ueno NT
Breast Cancer Res; 2013 Nov; 15(6):R112. PubMed ID: 24274653
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of inflammatory breast cancer.
Bertucci F; Finetti P; Birnbaum D; Viens P
Cancer; 2010 Jun; 116(11 Suppl):2783-93. PubMed ID: 20503410
[TBL] [Abstract][Full Text] [Related]
13. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract][Full Text] [Related]
14. Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin.
Ben Hamida A; Labidi IS; Mrad K; Charafe-Jauffret E; Ben Arab S; Esterni B; Xerri L; Viens P; Bertucci F; Birnbaum D; Jacquemier J
BMC Cancer; 2008 Jan; 8():28. PubMed ID: 18230143
[TBL] [Abstract][Full Text] [Related]
15. Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.
Goh G; Schmid R; Guiver K; Arpornwirat W; Chitapanarux I; Ganju V; Im SA; Kim SB; Dechaphunkul A; Maneechavakajorn J; Spector N; Yau T; Afrit M; Ahmed SB; Johnston SR; Gibson N; Uttenreuther-Fischer M; Herrero J; Swanton C
PLoS Med; 2016 Dec; 13(12):e1002136. PubMed ID: 27923043
[TBL] [Abstract][Full Text] [Related]
16. IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2.
Mohamed HT; El-Ghonaimy EA; El-Shinawi M; Hosney M; Götte M; Woodward WA; El-Mamlouk T; Mohamed MM
Toxicol Appl Pharmacol; 2020 Aug; 401():115092. PubMed ID: 32512068
[TBL] [Abstract][Full Text] [Related]
17. Clinicogenomic characterization of inflammatory breast cancer.
Priedigkeit N; Harrison B; Shue R; Hughes M; Li Y; Kirkner GJ; Spurr LF; Remolano MC; Strauss S; Files J; Feeney AM; Grant L; Mohammed-Abreu A; Garrido-Castro A; Sousa RB; Bychkovsky B; Nakhlis F; Bellon JR; King TA; Winer EP; Lindeman N; Johnson BE; Sholl L; Dillon D; Overmoyer B; Tolaney SM; Cherniack A; Lin NU; Lynce F
bioRxiv; 2024 May; ():. PubMed ID: 38766070
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer.
Wang L; Diao M; Zhang Z; Jiang M; Chen S; Zhao D; Liu Z; Zhou C
Lung Cancer; 2024 Jan; 187():107439. PubMed ID: 38113653
[TBL] [Abstract][Full Text] [Related]
19. A Pilot Study for the Feasibility of Exome-Sequencing in Circulating Tumor Cells Versus Single Metastatic Biopsies in Breast Cancer.
Kaur P; Campo D; Porras TB; Ring A; Lu J; Chairez Y; Su Y; Kang I; Lang JE
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32650480
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
